To assess the ability of MVA-EBV5-2-generated antibodies to prevent EBV infection in vivo, we performed vaccine efficacy studies in immunodeficient NOD scid gamma mice engrafted with human CD34+ hematopoietic stem cells (NSG huMice) (Figures 6A, 7A). This evidence concerns the gene CD34 and Epstein-Barr virus infection.